242 related articles for article (PubMed ID: 30477516)
1. The present and future burden of previously treated advanced non-small cell lung cancer (NSCLC) by histology and line of therapy in France, Germany, Italy, and Spain: model-based predictions.
Campbell D; O'Day K; Hertel N; Penrod JR; Manley Daumont M; Lees M
Popul Health Metr; 2018 Nov; 16(1):17. PubMed ID: 30477516
[TBL] [Abstract][Full Text] [Related]
2. Systemic Treatment Patterns With Advanced or Recurrent Non-small Cell Lung Cancer in Japan: A Retrospective Hospital Administrative Database Study.
Wang F; Mishina S; Takai S; Le TK; Ochi K; Funato K; Matsuoka S; Ohe Y
Clin Ther; 2017 Jun; 39(6):1146-1160. PubMed ID: 28527959
[TBL] [Abstract][Full Text] [Related]
3. Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study.
Lee DH; Tsao MS; Kambartel KO; Isobe H; Huang MS; Barrios CH; Khattak A; de Marinis F; Kothari S; Arunachalam A; Cao X; Burke T; Valladares A; de Castro J
PLoS One; 2018; 13(8):e0202865. PubMed ID: 30148862
[TBL] [Abstract][Full Text] [Related]
4. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
[TBL] [Abstract][Full Text] [Related]
5. Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study.
Lee DH; Isobe H; Wirtz H; Aleixo SB; Parente P; de Marinis F; Huang M; Arunachalam A; Kothari S; Cao X; Donnini N; Woodgate AM; de Castro J
BMC Health Serv Res; 2018 Mar; 18(1):147. PubMed ID: 29490654
[TBL] [Abstract][Full Text] [Related]
6. A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.
Nuijten MJ; de Castro Carpeño J; Chouaid C; Vergnenègre A; Grossi F; Bischoff H; Heigener D; Walzer S
Lung Cancer; 2012 Jun; 76(3):465-71. PubMed ID: 22153602
[TBL] [Abstract][Full Text] [Related]
7. Cost burden associated with advanced non-small cell lung cancer in Europe and influence of disease stage.
Wood R; Taylor-Stokes G
BMC Cancer; 2019 Mar; 19(1):214. PubMed ID: 30849964
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.
Banz K; Bischoff H; Brunner M; Chouaid C; de Castro Carpeño J; de Marinis F; Grossi F; Vergnenègre A; Walzer S
Lung Cancer; 2011 Dec; 74(3):529-34. PubMed ID: 21592611
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS).
Andreas S; Chouaid C; Danson S; Siakpere O; Benjamin L; Ehness R; Dramard-Goasdoue MH; Barth J; Hoffmann H; Potter V; Barlesi F; Chirila C; Hollis K; Sweeney C; Price M; Wolowacz S; Kaye JA; Kontoudis I
Lung Cancer; 2018 Oct; 124():298-309. PubMed ID: 29961557
[TBL] [Abstract][Full Text] [Related]
10. Treatment cost of non-small cell lung cancer in three European countries: comparisons across France, Germany, and England using administrative databases.
McGuire A; Martin M; Lenz C; Sollano JA
J Med Econ; 2015; 18(7):525-32. PubMed ID: 25802950
[TBL] [Abstract][Full Text] [Related]
11. Metastatic non-small-cell lung cancer without driver mutations: projections by therapy line in Western Europe, 2021-2026.
Zhu X; Durbin L; Kanas G; Phiri K; Keeven K; Clark O; Nersesyan K; Aziez A; Stojadinovic A; Bell KF
Future Oncol; 2023 Oct; 19(33):2237-2250. PubMed ID: 37529892
[TBL] [Abstract][Full Text] [Related]
12. Treatment, outcome and quality of life of 1239 patients with advanced non-small cell lung cancer - final results from the prospective German TLK cohort study.
von Verschuer U; Schnell R; Tessen HW; Eggert J; Binninger A; Spring L; Jänicke M; Marschner N;
Lung Cancer; 2017 Oct; 112():216-224. PubMed ID: 28916198
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
[TBL] [Abstract][Full Text] [Related]
14. The humanistic burden associated with caring for patients with advanced non-small cell lung cancer (NSCLC) in three European countries-a real-world survey of caregivers.
Wood R; Taylor-Stokes G; Lees M
Support Care Cancer; 2019 May; 27(5):1709-1719. PubMed ID: 30121787
[TBL] [Abstract][Full Text] [Related]
15. Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.
Nishiyama A; Katakami N; Yoshioka H; Iwasaku M; Korogi Y; Hata A; Takeshita J; Otsuka K; Nishino K; Uchida J; Okuyama T; Namba Y; Mori M; Fujita S; Morita S
Lung Cancer; 2015 Sep; 89(3):301-5. PubMed ID: 26141215
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
18. Referral patterns in advanced non-small cell lung cancer: impact on delivery of treatment and survival in a contemporary population based cohort.
Noonan K; Tong KM; Laskin J; Melosky B; Sun S; Murray N; Ho C
Lung Cancer; 2014 Dec; 86(3):344-9. PubMed ID: 25439436
[TBL] [Abstract][Full Text] [Related]
19. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.
Mazières J; Peters S; Lepage B; Cortot AB; Barlesi F; Beau-Faller M; Besse B; Blons H; Mansuet-Lupo A; Urban T; Moro-Sibilot D; Dansin E; Chouaid C; Wislez M; Diebold J; Felip E; Rouquette I; Milia JD; Gautschi O
J Clin Oncol; 2013 Jun; 31(16):1997-2003. PubMed ID: 23610105
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
